Publication: Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
Issued Date
2007-12-12
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-36549028324
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.25, No.51 (2007), 8585-8597
Suggested Citation
Pierre Vandepapelière, George K.K. Lau, Geert Leroux-Roels, Yves Horsmans, Edward Gane, Tawesak Tawandee, Mohd Ismail bin Merican, Khin Maung Win, Christian Trepo, Graham Cooksley, Martine Wettendorff, Carlo Ferrari Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine. Vol.25, No.51 (2007), 8585-8597. doi:10.1016/j.vaccine.2007.09.072 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24062
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
Other Contributor(s)
Queen Mary Hospital Hong Kong
Universiteit Gent
Cliniques Universitaires Saint-Luc, Brussels
Middlemore Hospital, Auckland
Mahidol University
Kuala Lumpur Hospital
Yangon General Hospital
Hopital de l'Hotel-Dieu CHU Lyon
University of Queensland
Glaxosmithkline Biologicals S.A.
Universita degli Studi di Parma
Universiteit Gent
Cliniques Universitaires Saint-Luc, Brussels
Middlemore Hospital, Auckland
Mahidol University
Kuala Lumpur Hospital
Yangon General Hospital
Hopital de l'Hotel-Dieu CHU Lyon
University of Queensland
Glaxosmithkline Biologicals S.A.
Universita degli Studi di Parma
Abstract
Induction of curative immune responses by therapeutic vaccination in chronic viral infections such as chronic hepatitis B (CHB) is expected to be facilitated by reduction of viral load by antiviral treatment. In this open label, controlled, randomized study, 195 patients with HBeAg positive CHB were randomized to receive 12 doses of HBsAg with AS02B adjuvant candidate vaccine plus lamivudine daily for 52 weeks or lamivudine daily alone. The combined administration of vaccine and lamivudine was safe and well tolerated, but did not improve the HBe seroconversion rate (18.8%) when compared to treatment with lamivudine alone (16.1%) (p = 0.6824). Despite induction of a vigorous HBsAg-specific lymphoproliferative response, cytokine production and anti-HBs antibodies, therapeutic vaccination with an adjuvanted HBsAg vaccine administered concomitantly with lamivudine did not demonstrate superior clinical efficacy in HBeAg positive CHB patients as compared to lamivudine therapy alone. © 2007 Elsevier Ltd. All rights reserved.